On July 27, 2021, Zhongze’s CNS R&D platform was officially launched in Zhangjiang Pharma Valley, Shanghai. This is an important milestone in the history of ZHONGZE as it will further expediateZHONGZE’s progress in its CNS R&D endeavors.

   At 15:00, shareholders, strategic partners and employees of ZHONGZE gathered. Mr. Wanjun Ma, Chairman of ZHONGZE, started the opening ceremony by encouraging all members of the company to work together to realize our goals. 

    The official launch of the CNS R&D platform will open a new chapter in innovative CNS drug R&D. Standing at a new historical starting point, we are soberly aware of the difficulties and challenges ahead.At the same time, we are even more determined in our mission to serve CNS patients’ unmet medical needs. Our ultimate goal is to build an internationally renowned CNS drug company through the development of innovative and transformative CNS drugs. Our highest priority is to improve the lives of CNS patients and their loved ones, and to this end we are determined to create highly effective new medicines that will do just that.